Results 41 to 50 of about 40,633 (287)

Transthyretin levels in the vitreous correlate with change in visual acuity after vitrectomy [PDF]

, 2009
Background/aim: Little is known about biochemical markers related to change in visual acuity after vitrectomy. The potential use of transthyretin (TTR), a carrier of the retinol/retinol-binding protein, as a biochemical marker protein, was investigated ...
De Letter, Els, Delanghe, Joris, Delanghe, S, Derycke, Lara, Geers, I, Van Aken, Elisabeth, van Enschot, T, Veckeneer, M   +7 more
core   +3 more sources

Systemic amyloidosis in England: an epidemiological study. [PDF]

, 2013
Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Banypersad, SM, Dungu, J, Gibbs, SD, Gillmore, JD, Hawkins, PN, Lachmann, HJ, Pinney, JH, Smith, CJ, Taube, JB, Venner, CP, Wechalekar, AD, Whelan, CJ   +11 more
core   +1 more source

Case Report and Literature Review of Cardiac Amyloidosis: A Not-So-Rare Cause of Heart Failure [PDF]

, 2023
Restrictive cardiomyopathy secondary to cardiac amyloidosis is an underdiagnosed cause of heart failure and it is associated with significant morbidity and mortality.
Alexandre, André, Baptista, Patrícia, Dias-Frias, André, Moura De Azevedo, Sofia   +3 more
core   +1 more source

Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac amyloidosis (CA) is frequently found in older patients with aortic stenosis (AS). However, the prevalence of AS among patients with CA is unknown.
Mohamed‐Salah Annabi, Rasmus Carter‐Storch, Amira Zaroui, Arnault Galat, Silvia Oghina, Mounira Kharoubi, Mélanie Bezard, Geneviève Derumeaux, Pascale Fanen, François Lemonnier, Elsa Poullot, Emmanuel Itti, Romain Gallet, Emmanuel Teiger, Philippe Pibarot, Thibaud Damy, Marie‐Annick Clavel   +16 more
doaj   +1 more source

Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Ioan Alexandru Minciună, Ruxandra Beyer, Raluca Tomoaia, Alina Chirilă, Dana Pop, Alexandra Dădârlat-Pop, Simona Manole   +6 more
openaire   +3 more sources

Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy [PDF]

, 2015
Background: Hypertrophic cardiomyopathy (HCM) is a common cardiac disease caused by a range of genetic and acquired disorders. The most common cause is genetic variation in sarcomeric proteins genes.
Rosmini, Stefania <1981>
core   +1 more source

Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis [PDF]

, 2016
Search strategy.
Lei Zhao, Quan Fang, Zhuang Tian
core   +2 more sources

Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study

ESC Heart Failure
Aims Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated biomarker levels and limited thresholds for stratifying severe cardiac damage.
Amira Zaroui, Mounira Kharoubi, Romain Gounot, Silvia Oghina, Charlotte Degoutte, Melanie Bezard, Arnault Galat, Soulef Guendouz, Louise Roulin, Vincent Audard, Vincent Leroy, Emmanuel Teiger, Elsa Poullot, Valérie Molinier‐Frenkel, Fabien Le Bras, Karim Belhadj, Jean‐Philippe Bastard, Soraya Fellahi, Jason Shourick, Francois Lemonier, Thibaud Damy   +20 more
doaj   +1 more source

Case Report: Diagnosis of Dual-Biopsy Negative Severe Cardiac Amyloidosis [PDF]

, 2016
INTRODUCTION Amyloidosis is a rare disorder that involves the deposition of misfolded protein in extracellular tissue. Disease manifestations vary depending on the affected organs.
Kasprowicz, MD, Eric, Lohr, MD, Kristin
core   +2 more sources

Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery

Aggregate, EarlyView.
This review highlights recent progress in cell membrane‐coated lipid nanoparticles (CMC‐LNPs), focusing on their design, preparation methods, functional integration, and biomedical applications. It discusses various types of LNPs and coating strategies, characterization techniques, therapeutic functions, and applications.
Moataz B. Zewail, Guangze Yang, Yilong Fan, Yue Hui, Chun‐Xia Zhao, Yun Liu   +5 more
wiley   +1 more source